Want to join the conversation?
Medical technology company $MDT said its clinical data on the Harmony(TM) Transcatheter Pulmonary Valve early feasibility study showed positive initial outcomes at 6 months in patients with an indication for pulmonary valve restoration. A pivotal Investigational Device Exemption study is planned to start in late 2016, pending approval from the FDA.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.